Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases
NCT01884311Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Aug 2015
- Primary completion
- May 2017
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Subgam in primary immunodeficiency disease (PID), sponsored by Bio Products Laboratory. Primary endpoint: Log Transformed sAUC0-t Standardized to One Week at 1 week. Started Aug 2015; status: completed.
02
Drugs
Subgam
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT01884311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01884311.